Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy

Cell Stem Cell. 2018 Aug 2;23(2):160-161. doi: 10.1016/j.stem.2018.07.007.

Abstract

CAR-T therapy has shown great success treating blood cancers, but drawbacks include high manufacturing costs and potentially fatal toxicities such as cytokine release syndrome. In this issue of Cell Stem Cell, Li et al. (2018) describe how engineered iPSC-derived NK cells armed with NK-tailored CAR constructs (CAR-iPSC-NK cells) provide better options for anti-cancer immunotherapy.

Publication types

  • Comment

MeSH terms

  • Humans
  • Immunotherapy, Adoptive*
  • Killer Cells, Natural
  • Neoplasms*
  • Receptors, Chimeric Antigen

Substances

  • Receptors, Chimeric Antigen